{"id":2116265,"date":"2023-12-05T12:23:02","date_gmt":"2023-12-05T17:23:02","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/eli-lillys-obesity-drug-now-available-in-u-s-pharmacies\/"},"modified":"2023-12-05T12:28:14","modified_gmt":"2023-12-05T17:28:14","slug":"eli-lillys-obesity-drug-now-available-in-u-s-pharmacies","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/eli-lillys-obesity-drug-now-available-in-u-s-pharmacies\/","title":{"rendered":"Eli Lilly&#8217;s obesity drug now in US pharmacies"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"&quot;\"><div class=\"counts mashsbcount\">16<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Feli-lillys-obesity-drug-now-available-in-u-s-pharmacies%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=2116265&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><p><!DOCTYPE html PUBLIC \"-\/\/W3C\/\/DTD HTML 4.0 Transitional\/\/EN\" \"http:\/\/www.w3.org\/TR\/REC-html40\/loose.dtd\"><br \/>\n<?xml encoding=\"utf-8\" ?><?xml encoding=\"utf-8\" ?><?xml encoding=\"utf-8\" ?><html><body><\/p>\n<div class=\"entry-content\">\n<h2>Breaking News: Eli Lilly Launches Zepbound, the New Obesity\u200c Treatment<\/h2>\n<p>December 5, \u20632023 \u2013 3:36\u200d PM UTC<\/p>\n<p>(Reuters) \u2013 Eli Lilly (LLY.N) \u2064announced today that its highly anticipated obesity treatment, Zepbound, is now available in U.S. pharmacies.\u200d For customers without health insurance coverage,\u2063 the drug may cost $550 per month, which is half the list \u2062price.<\/p>\n<div id=\"div-gpt-ad-1663871513696-art-3\" style=\"min-width: 320px; min-height: 50px; text-align: center;\">  \t<script>  \t\tgoogletag.cmd.push(function() { googletag.display('div-gpt-ad-1663871513696-art-3'); });  \t<\/script>  <\/div>\n<div class=\"ad-slot__ad-label\">Advertisement<\/div>\n<\/p>\n<p>Zepbound is the latest entrant to the fast-growing market for <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/doctors-say-these-are-the-four-most-effective-weight-loss-drugs\/\" title=\"Doctors Say These Are the Four Most Effective Weight-loss Drugs\">weight-loss drugs<\/a>, which is\u2064 expected to reach a staggering $100 billion \u2063by the end of the decade.<\/p>\n<p>Excitingly, Wall \u2064Street analysts \u2062predict that Zepbound&#8217;s sales will soar\u2064 to approximately $2 billion \u200cin 2024. According to Barclays analyst Emily Field, Novo Nordisk&#8217;s powerful\u2062 obesity drug, Wegovy, is \u2063projected to generate an impressive $7.3\u2062 billion in sales next year.<\/p>\n<p>Both Zepbound and Wegovy belong to the class of GLP-1 agonists, originally \u200ddesigned to treat \u2062type 2 diabetes.<\/p>\n<p>Notably, Zepbound has been added to the U.S. list of\u200b preferred medicines by Cigna (CI.N),\u200d a major drug benefits company.<\/p>\n<p>Pharmacy benefit\u200c managers compile\u200b formularies, which are lists\u200d of medications covered by insurance and for which pharmacies are reimbursed for patients&#8217; prescriptions.<\/p>\n<p>Lilly has introduced \u200ca commercial savings card program, available at various pharmacy chains. Through this program, patients with insurance coverage may pay as little as $25 for Zepbound, while those without insurance may \u200dpay $550.<\/p>\n<p>The U.S. Food and \u2063Drug Administration granted approval for Zepbound\u200c in November, \u2064and Lilly promptly announced \u2063its launch after Thanksgiving.<\/p>\n<p>Compared to Novo&#8217;s popular Wegovy, Zepbound has a list price of $1,059.87 per month, significantly lower than Wegovy&#8217;s $1,349 per \u2062package.<\/p>\n<p>It is worth noting that Lilly&#8217;s \u2064obesity drug, Zepbound, shares the same active ingredient, tirzepatide, \u200bas its previously approved diabetes drug, Mounjaro, which has been \u200cused\u200c off-label \u2063for \u200bweight loss since its launch in 2022.<\/p>\n<p>Eli Lilly&#8217;s shares have skyrocketed by \u200c60% this year in anticipation\u2062 of the Zepbound launch, propelling the drugmaker to the tenth spot on the list\u2063 of the world&#8217;s most valuable listed companies by market capitalization.<\/p>\n<p><sub>Reporting by Patrick Wingrove in New York and Manas Mishra and Khushi Mandowara in Bengaluru; Editing by Arun Koyyur and Alexander Smith<\/sub><\/p>\n<\/p>\n<div id=\"rc-widget-10bad2\" data-rc-widget data-widget-host=\"habitat\" data-endpoint=\"\/\/trends.revcontent.com\" data-widget-id=\"278641\"><\/div>\n<p class=\"dpsp-share-text\" style=\"margin-bottom:10px\"> \t\t \t\tShare this post!\t<\/p>\n<\/p><\/div>\n<div class=\"entry-content\">\n<h3>Related Articles:<\/h3>\n<\/p><\/div>\n<div class=\"entry-content\">\n<ul>\n<li>Interview with Jeff Zink &#038; Ryan Zink<\/li>\n<\/ul><\/div>\n<div class=\"entry-content\">\n<ul>\n<li>Interview with Hans Mahncke<\/li>\n<\/ul><\/div>\n<div class=\"entry-content\">\n<ul>\n<li>Interview with Jim\u2062 Nelles<\/li>\n<\/ul><\/div>\n<div class=\"entry-content\">\n<h3>Other\u2064 Headlines:<\/h3>\n<\/p><\/div>\n<div class=\"entry-content\">\n<ul>\n<li>James Comer links Joe Biden to \u2062Hunter\u2019s company Owasco PC, a Jewish diner is under siege and Ireland looks to crush free speech.<\/li>\n<\/ul><\/div>\n<div class=\"entry-content\">\n<ul>\n<li>A group representing 83 Spanish media outlets has filed a $600 million\u200d lawsuit against Facebook owner Meta Platforms.<\/li>\n<\/ul><\/div>\n<div class=\"entry-content\">\n<ul>\n<li>Verizon said it would offer streaming subscriptions to \u200bNetflix \u2062and Warner Bros Discovery-owned Max platforms as a bundle to its customers.<\/li>\n<\/ul><\/div>\n<div class=\"entry-content\">\n<ul>\n<li>Market capitalizations of <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/cdc-advises-against-eating-pre-cut-cantaloupe-as-salmonella-outbreak-escalates\/\" title=\"CDC warns against pre-cut cantaloupe due to escalating salmonella outbreak\">global mega-cap \u2064companies surged<\/a>,\u200b buoyed by a decline in U.S. yields and growing \u2062anticipation of <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/decolonization-part-of-radical-climate-agenda\/\" title=\"Decolonization' in Radical Climate Agenda\">potential rate cuts amid diminishing worries<\/a> about inflation.<\/li>\n<\/ul><\/div>\n<div class=\"entry-content\">\n<ul>\n<li>More advertisers are likely to flee Elon Musk\u2019s <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/the-new-acting-attorney-general-jeff-rosen-recently-wrote-an-essay-on-foreign-influence-in-us-elections-this-tells-us-a-little-about-his-knowledge-of-whats-going-on-today\/\" title=\"The New Acting Attorney General Jeff Rosen Recently Wrote an Essay on Foreign Influence in US Elections \u2013 This Tells Us A Little About His Knowledge of What\u2019s Going On Today\">social media platform<\/a> X after the billionaire lashed out at some of the biggest names in the \u2064media industry.<\/li>\n<\/ul><\/div>\n<p> rnrn  <\/p>\n<h2> What sets Zepbound apart from other weight-loss drugs, such as Wegovy, in terms of projected sales and market potential?<\/h2>\n<p><span>  On. The \u2064success of Zepbound has been highly\u200d anticipated due\u2063 to the growing demand for effective obesity treatments.<\/p>\n<p>Zepbound, developed by Eli Lilly, is now available in U.S. \u2064pharmacies. What\u200b sets this drug apart is its\u200b relatively affordable price. For customers without\u2064 health insurance coverage, Zepbound may cost \u200b$550 per month,\u200c which is significantly lower than\u2064 the list price. This affordability makes it\u2064 more accessible to a larger number of people struggling with obesity.<\/p>\n<p>The weight-loss drug market is rapidly expanding and is predicted to reach a staggering $100 billion by the end of the\u200b decade. Analysts on Wall \u2064Street are optimistic about Zepbound&#8217;s potential, with predicted sales of around\u200c $2 billion in 2024. Comparatively, Novo Nordisk&#8217;s obesity drug, Wegovy, is projected to generate $7.3\u2062 billion in sales next year.<\/p>\n<p>Zepbound and \u200cWegovy belong to the class of GLP-1 agonists, initially designed to treat \u2062type 2 diabetes. Their effectiveness in helping patients lose weight has\u2064 made them valuable in the fight\u2063 against obesity.<\/p>\n<p>Cigna, a major drug benefits company, has recognized the \u200cvalue of \u2062Zepbound and \u200badded it to its list of preferred medicines. This means that more patients will have access to the drug through their insurance coverage, making it easier for them to afford the treatment.<\/p>\n<p>To further assist patients, Eli Lilly has introduced a commercial savings\u2062 card program, \u200davailable\u2064 at various pharmacy chains. This program\u200b allows patients with insurance coverage to pay as little as $25 for Zepbound, while those without\u2064 insurance may still\u200c benefit from the drug at a price\u2062 of $550.<\/p>\n<p>In November, the U.S. Food\u2064 and \u2063Drug Administration granted approval\u200c for Zepbound, and Eli\u2062 Lilly wasted no time in announcing its launch after Thanksgiving. Compared to Wegovy, Zepbound\u2062 has a lower list price of $1,059.87\u2063 per month, providing a more\u2062 affordable option for patients seeking weight-loss solutions.<\/p>\n<p>It\u200c is important to note \u200bthat\u2064 Zepbound shares the\u200c same active ingredient, tirzepatide, as\u200b Eli Lilly&#8217;s previously approved diabetes drug, Mounjaro. Since \u2063its launch in\u200d 2022, Mounjaro has been used off-label \u2063for weight loss, further demonstrating the potential of \u200dtirzepatide in combating obesity.<\/p>\n<p>The launch of Zepbound has had a significant impact on Eli Lilly&#8217;s stock performance, with their shares skyrocketing by \u200c60% this year. \u200dThis \u2063exceptional growth has propelled \u2062the company to \u200cthe tenth spot on the list\u2063 of the world&#8217;s most valuable listed companies by market capitalization.<\/p>\n<p>The availability\u2063 of Zepbound offers new hope for individuals struggling with obesity. With its lower price and promising effectiveness, it is expected to make\u200c a\u2062 significant impact on the weight-loss drug market. As more patients gain access to this treatment, the \u200cfight against \u200cobesity continues to receive a powerful boost.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. obesity treatment market. Eli Lilly announced that the drug is now accessible in American pharmacies. Customers without insurance coverage may have to pay $550 per month, which is half the list price. Zepbound aims to tackle the issue of obesity<\/p>\n","protected":false},"author":1911,"featured_media":2116266,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[542],"tags":[],"class_list":["post-2116265","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oann"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2116265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/1911"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=2116265"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/2116265\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2116266"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=2116265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=2116265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=2116265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}